AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Small-cap and mid-cap stocks research hub covering catalysts, earnings, capital structure and volatility
Merlintrader research directory · Non-biotech

Small and Mid Caps: $SPSC, $CLF, $EFOR, $FSLY and $PENG

Week of November 16–20, 2026. The same five company cases, re-examined at the November 13 close after a rebound week: four of the five rose, led by Penguin Solutions (+13.22%) and Cleveland-Cliffs (+10.38%), and their unweighted average of +6.25% beat IWM’s +1.41%. SPS Commerce, -0.74%, was the exception. The rebound did not repair the charts: none of the five closed above both of its moving averages, and Fastly and Penguin remain far below them. None of the five reports results this week. Dated company evidence, cash-flow risks and chart conditions guide the research; none supplies a promised positive week.

5 casesResearch statuses and risks stated individually
+6.25%Previous five · Nov 6–13 price audit
+1.41%IWM · identical audit interval
Nov 13Latest completed U.S. session

Read the business, the cash and the market together

Small and mid caps can react sharply to financing, a single customer, operating leverage or a change in expectations. A higher share price does not resolve those risks. This week’s work separates reported operating progress from management forecasts, identifies where earnings and cash generation diverge, and keeps contract ceilings distinct from booked revenue.

Small and mid caps rose, but small caps lagged large caps. From November 6 to November 13, IWM changed +1.41%, MDY +2.26% and SPY +2.59%. IWM reached a $283.79 intraday high on November 9 and then gave back part of the move; its $277.54 close is below SMA20 $278.38 and SMA50 $280.76, and its intermediate average declined 1.24% over ten sessions. MDY closed above both of its averages, SPY below both. After three weeks in which smaller companies held up better in relative terms, IWM trailed SPY this week. The coming week has no Federal Reserve meeting; the Census Bureau publishes October retail sales on November 17, and NVIDIA reports its fiscal third quarter after the close the same day.

These are research comparisons, not a ranked model portfolio. The scope is U.S.-listed non-healthcare equities in an indicative $300 million–$10 billion market-value band. No allocation, entry recommendation, price objective or probability-of-success claim is made.

Five researched cases: confirmation, cash and timing

November 16–20 · closes through November 13

This edition re-examines the same five cases at the November 13 close instead of replacing them. In the fixed audit week four of the five rose and four beat IWM; SPSC was the only one to fall. CLF closed back above $12.62, the ten-session low named two weeks ago as the level that would change its reading, and above SMA50, but its invalidation is not erased: the label records what happened. EFOR closed every session above $35.37, PENG recovered part of its decline and FSLY stayed close to its November 5 low. Every case stays in the list with its updated label, so the record can be checked. Detailed daily-price work covered 23 individual equities and three benchmark ETFs: the five cases and the same 18 names checked in the previous edition. This is a finite editorial selection, not an exhaustive market ranking.

A partial recovery, a reclaimed level and a quiet consolidation · The two technology cases · Week-ahead calendar · Previous-edition audit · Other checked names

TickerCompanyNov 13 close · USDNov 6–13 price changevs IWM · percentage pointsResearch statusWhy it is on the list
$SPSCSPS Commerce81.30-0.74%-2.16 ppBreakout failed · holding above $79.00Traded between $79.32 and $84.00 and closed below both averages, above the $79.00 ten-session low. The chief technology officer exercised options and sold 11,196 shares on November 6 (Form 4 filed November 10).
$CLFCleveland-Cliffs12.65+10.38%+8.97 ppInvalidated · back above $12.62 and SMA50Recovered from $11.46 to a $13.65 intraday high on November 12 and closed at $12.65, just above SMA50 and below SMA20. On November 13 Stelco said it will recall 175 Hamilton workers on December 1.
$EFOREverforth35.55+3.52%+2.11 ppFailed · stabilizing just below SMA50Closed every session of the week between $35.55 and $35.99, above the $35.37 reference and just below SMA50 $35.63; no new company release or periodic report.
$FSLYFastly16.62+4.86%+3.44 ppFailed status retained · far below both averagesRose from $15.85 to $16.62, still 21% below SMA20. A 10-K/A corrected an omitted sentence, and Form 144 notices covered planned sales of 121,715 shares by four officers.
$PENGPenguin Solutions47.36+13.22%+11.81 ppReassessment · rebound still below both averagesRebounded to a $51.22 intraday high on November 12 and closed at $47.36, below both averages. A prospectus supplement named an SK hynix entity as the selling holder of the convertible preferred.

The prior-week return describes what happened before this edition. It does not predict next week. The fixed forward comparison is November 13 close to November 20 close, against IWM over the same interval. Its ending close is not yet available. All five cases, including the CLF invalidation, the EFOR and FSLY failures and the PENG reassessment, remain in that future audit; no failed or unconfirmed name may be removed retrospectively.

A partial recovery, a reclaimed level and a quiet consolidation

$SPSC · SPS Commerce

Breakout failed · holding above $79.00: the only case that fell in a rebound week

November 13 close $81.30 · SMA20 $85.35 · SMA50 $83.39 · volume/prior20 0.39× · Live chart

What changed this week. A Form 4 filed November 10 reports that Jamie Thingelstad, executive vice president and chief technology officer, exercised fully vested options on 11,196 shares at $56.25 on November 6 and sold the same number of shares that day at a weighted average of $81.59, in multiple trades between $81.35 and $81.91; he holds 95,777 shares directly after the sale. A Schedule 13G filed November 13 by Neuberger Berman reports a 6.0% holding as of September 30. Neither filing changes the business data. Form 4 · filed November 10 · Schedule 13G.

Business evidence, unchanged. For the quarter ended September 30 the company reported revenue of $197.6 million, up 4%, adjusted EBITDA up 17% to $70.9 million and diluted earnings of $0.85 per share; full-year guidance calls for revenue of $786.9–$788.9 million, about 5% growth, with an adjusted EBITDA margin of about 34%. Margins are rising on a business growing at a mid-single-digit rate. SEC earnings exhibit.

What happened in the chart. SPSC traded between $79.32 on November 10 and $84.00 on November 12 and closed at $81.30: -0.74% for the week and 2.16 percentage points behind IWM. The close is below SMA20 $85.35 and SMA50 $83.39; the intermediate average is flat over ten sessions (+0.01%). The $79.00 November 6 intraday low remains the ten-session low and was not broken.

Participation. November 13 volume was 0.39 times the preceding 20-session average, and the latest 20-session average is about 522,000 shares, still just above the preferred 500,000-share research threshold. A quiet range on falling volume is not, by itself, evidence of accumulation or distribution.

How to read the next weeks. A constructive reading would still need closes back above the $89.00–$89.44 area with broad participation; closes below $79.00 would weaken the consolidation further. These are chart references, not entry or stop orders.

Primary sources: November 10 Form 4 · November 13 Schedule 13G · October 29 SEC earnings exhibit · September 30 Form 10-Q. Company figures retain the reporting dates stated above; all chart figures use November 13 prices.

SPSC · 60 daily sessions · USD
64.1071.5679.0186.4793.9208-2109-1410-0510-2611-13Daily share volume · common scale within this chart

Blue: SMA20. Purple: SMA50. Green candles close at or above their open; red candles close below it. Lower bars show each session’s share volume. The chart contains historical observations, with no projected prices.

Source: daily bars through November 13, 2026. Moving averages calculated by Merlintrader from the same series. The displayed window is August 21–November 13; earlier observations supply the averages.

$CLF · Cleveland-Cliffs

Invalidated · back above $12.62 and SMA50: a recovery that does not erase the invalidation

November 13 close $12.65 · SMA20 $13.32 · SMA50 $12.61 · volume/prior20 0.52× · Live chart

What changed this week. Cleveland-Cliffs filed no new SEC document between November 7 and November 13. On November 13 its Canadian subsidiary Stelco announced that it had reached agreement with enough customers to restart its Hamilton finishing operations for cold-rolled and coated products, whose temporary idling it had announced on September 28, and to recall all 175 affected workers on December 1. The release gives no volumes, prices or financial impact. The four-year United Steelworkers agreements announced on November 6 remain subject to ratification. November 13 Stelco release · November 6 labor agreements.

Business evidence from the October 19 report. Third-quarter revenue was $5.6 billion, GAAP net income $165 million, or $0.26 per diluted share, and adjusted EBITDA $612 million; long-term debt was $7.645 billion at September 30, with $77 million of cash. The leverage target of under 2.5 times net debt to EBITDA by mid-2027 remains a goal that depends on forecast earnings. September 30 Form 10-Q.

What happened in the chart. CLF rose from $11.46 to a $13.65 intraday high on November 12 and closed the week at $12.65: +10.38% and 8.97 percentage points ahead of IWM. The close is above SMA50 $12.61 by a few cents and below SMA20 $13.32, and it is back above the $12.62 level whose break invalidated the post-results reading two weeks ago. Volume stayed between 0.42 and 0.53 times the prior-20 average in every session, an average that still includes the heavy sessions after the October 19 report.

How to read the next weeks. The invalidation stays in the record: a recovery after a broken level is a new observation, not a reversal of the old one. A new constructive reading would need closes above SMA20 and the $15.03 prior-20-session high on better participation; the $11.25 November 5 intraday low remains the ten-session low. Steel prices, import policy, the ratification of the labor agreements and the fourth-quarter results remain the business variables. These are chart references, not entry or stop orders.

Primary sources: November 13 Stelco release · November 6 labor agreements · October 19 quarterly results · September 30 Form 10-Q. Company figures retain the reporting dates stated above; all chart figures use November 13 prices.

CLF · 60 daily sessions · USD
10.6611.8012.9314.0615.2008-2109-1410-0510-2611-13Daily share volume · common scale within this chart

Blue: SMA20. Purple: SMA50. Green candles close at or above their open; red candles close below it. Lower bars show each session’s share volume. The chart contains historical observations, with no projected prices.

Source: daily bars through November 13, 2026. Moving averages calculated by Merlintrader from the same series. The displayed window is August 21–November 13; earlier observations supply the averages.

$EFOR · Everforth

Failed · stabilizing just below SMA50: a narrow range above $35.37

November 13 close $35.55 · SMA20 $37.69 · SMA50 $35.63 · volume/prior20 0.63× · Live chart

What changed this week. Everforth published no new release or periodic report between November 7 and November 13. A Schedule 13G/A filed November 12 by AQR Capital Management reports 2.88% of the shares as of September 30, below the 5% reporting threshold. The November 3 extension of up to two years of a National Geospatial-Intelligence Agency contract, with a potential value of more than $200 million, remains a ceiling over its life, not booked revenue. Schedule 13G/A · November 3 announcement.

Business evidence from the October 28 report. Third-quarter revenue was $1,031.4 million against $1,011.4 million a year earlier; net income fell to $23.1 million, or $0.56 per diluted share, and adjusted EBITDA to $106.3 million, a 10.3% margin. Fourth-quarter guidance calls for revenue of $965–$995 million and adjusted EBITDA of $93–$103 million. September 30 cash was $147.5 million against a $485 million term loan and $541 million of notes. SEC earnings exhibit.

What happened in the chart. EFOR opened the week at its $34.11 low on November 9, closed every session between $35.55 and $35.99 and ended at $35.55: +3.52% for the week and 2.11 percentage points ahead of IWM. The close is above the $35.37 level named two weeks ago, below SMA20 $37.69 and just below SMA50 $35.63. Volume was below its prior-20 average in every session; November 13 volume was 0.63 times that average.

How to read the next weeks. A narrow range after a failure is a pause, not a rebuilt case. A return above $40.33 on participation remains the condition for rebuilding the breakout reading, about 13% above the close; the $34.00 November 6 intraday low is the ten-session low. These are chart references, not entry or stop orders.

Primary sources: November 12 Schedule 13G/A · November 3 NGA announcement · October 28 SEC earnings exhibit · September 30 Form 10-Q. Company figures retain the reporting dates stated above; all chart figures use November 13 prices.

EFOR · 60 daily sessions · USD
22.4527.9733.5039.0344.5608-2109-1410-0510-2611-13Daily share volume · common scale within this chart

Blue: SMA20. Purple: SMA50. Green candles close at or above their open; red candles close below it. Lower bars show each session’s share volume. The chart contains historical observations, with no projected prices.

Source: daily bars through November 13, 2026. Moving averages calculated by Merlintrader from the same series. The displayed window is August 21–November 13; earlier observations supply the averages.

The two technology cases: a rebound from the November 5 lows

$FSLY · Fastly

Failed status retained · far below both averages: a rebound inside a falling trend

November 13 close $16.62 · SMA20 $21.06 · SMA50 $23.47 · volume/prior20 0.54× · Live chart

What changed this week. On November 10 Fastly filed a 10-K/A for 2025 to add to Item 9A a sentence with management’s assessment of internal control over financial reporting at December 31, 2025, which the company says was omitted from the original February filing by a typographical error; no other part of the annual report was changed. On November 12 the company announced that it had been named a Leader in Gartner’s 2026 Magic Quadrant for Edge Distribution Platforms; the placement is the company’s description of a third-party report, not a financial figure. Form 10-K/A · November 12 release.

Planned insider sales. On November 13 four Form 144 notices reported planned sales of restricted-stock shares by chief executive officer Charles Compton, chief financial officer Richard Wong, director and officer Artur Bergman and Scott Lovett, President, Go to Market: 121,715 shares in total, about $1.95 million at the values stated in the notices, with an approximate sale date of November 17. A Form 144 is a notice of intent; executed sales appear later in Form 4 filings. Form 144 · example filing.

Business evidence from the November 4 report. Third-quarter revenue was $190.2 million, up 20%, with security revenue up 32%; the GAAP net loss narrowed to $11.3 million and company-defined free cash flow was $25.2 million. Remaining performance obligations of $333.5 million were below the $340.9 million of the second quarter, and the top ten customers accounted for 39% of revenue. Guidance calls for fourth-quarter revenue of $198–$202 million. SEC earnings exhibit · Investor supplement.

What happened in the chart. FSLY rose from $15.85 to $16.62: +4.86% and 3.44 percentage points ahead of IWM. It set a $15.22 intraday low on November 10, just above the $15.20 November 5 low, and a $17.97 high on November 11. The close is 21.08% below SMA20 $21.06 and below SMA50 $23.47, and the intermediate average declined 4.07% over ten sessions.

Why the failed status is kept. The rebuild condition stated in previous editions, a sustained recovery of the intermediate average followed by closes above SMA20, has not been approached: SMA20 is more than four dollars above the price. Customer concentration and the sequential dip in remaining performance obligations are the business variables for the next report. These are chart references, not entry or stop orders.

Primary sources: November 10 Form 10-K/A · November 12 release · November 13 Form 144 · November 4 SEC earnings exhibit · September 30 Form 10-Q. Company figures retain the reporting dates stated above; all chart figures use November 13 prices.

FSLY · 60 daily sessions · USD
14.5518.9123.2727.6231.9808-2109-1410-0510-2611-13Daily share volume · common scale within this chart

Blue: SMA20. Purple: SMA50. Green candles close at or above their open; red candles close below it. Lower bars show each session’s share volume. The chart contains historical observations, with no projected prices.

Source: daily bars through November 13, 2026. Moving averages calculated by Merlintrader from the same series. The displayed window is August 21–November 13; earlier observations supply the averages.

$PENG · Penguin Solutions

Reassessment · rebound still below both averages: a 13% week that leaves the averages above

November 13 close $47.36 · SMA20 $51.36 · SMA50 $55.50 · volume/prior20 0.45× · Live chart

What changed this week. A prospectus supplement dated November 10 updates the selling-securityholder table of the resale prospectus covering up to 6,096,103 common shares issuable on conversion of 200,000 convertible preferred shares: SHIFTIX1, an indirect subsidiary of SK hynix, replaces the SK Telecom entity after the transfer already reported on November 2–3. The supplement does not increase the number of shares registered. On November 12 the company launched AI Platform Operations Services, a managed operations offering for AI infrastructure with tiers up to 24×7 multi-site support; the release names no customers and gives no financial figures. A Schedule 13G/A filed by Invesco reports 6.3% as of September 30. Prospectus supplement · November 12 release · Schedule 13G/A.

Business context. The November 4 agreement to sell the Cree LED business to an affiliate of Transom Capital Group, in an all-cash transaction expected to close in the first calendar quarter of 2027 and at an undisclosed price, remains pending; the company reaffirmed its fiscal 2027 outlook, which includes Cree LED at about 10% of projected net sales. Form 8-K · press release exhibit.

What happened in the chart. PENG rose from $41.83 to a $51.22 intraday high on November 12 and closed the week at $47.36: +13.22% and 11.81 percentage points ahead of IWM. The close is 7.78% below SMA20 $51.36 and below SMA50 $55.50, and the intermediate average declined 1.25% over ten sessions. Volume stayed below its prior-20 average in every session, an average inflated by the early-November sell-off.

How to read the next weeks. A rebound of this size after a fall of this size is consistent with unstable price discovery rather than a confirmed reversal. A reassessment would still need closes back above SMA50 on better volume; the $37.02 November 5 intraday low remains the ten-session low. Collections, cash absorption, the pending divestiture and dilution remain the risks. No price objective or success probability is assigned.

Primary sources: November 10 prospectus supplement · November 12 release · Schedule 13G/A · November 4 Form 8-K · Schedule 13D · filed November 3 · Form 10-K. Company figures retain the reporting dates stated above; all chart figures use November 13 prices.

PENG · 60 daily sessions · USD
35.2847.0158.7570.4882.2108-2109-1410-0510-2611-13Daily share volume · common scale within this chart

Blue: SMA20. Purple: SMA50. Green candles close at or above their open; red candles close below it. Lower bars show each session’s share volume. The chart contains historical observations, with no projected prices.

Source: daily bars through November 13, 2026. Moving averages calculated by Merlintrader from the same series. The displayed window is August 21–November 13; earlier observations supply the averages.

The week ahead: retail sales, NVIDIA and no company reports

Times are U.S. Eastern Time; Rome is six hours ahead. There is no Federal Open Market Committee meeting this week; the next one is scheduled for December 8–9. None of the five companies has a results date inside the window. Scheduled releases can be revised. A date indicates when information may arrive, not the direction of the result.

Date and timeVerified eventWhat the research can assess
Tue Nov 17 · 08:30 ET / 14:30 RomeAdvance retail sales, October 2026 (Census schedule); import and export prices, October (BLS schedule).Consumer-demand and imported-inflation background; neither identifies demand at an individual issuer.
Tue Nov 17 · after market closeNVIDIA third-quarter fiscal 2027 results; conference call at 5 p.m. ET. Company announcement.AI-infrastructure demand read-through for Penguin Solutions and Fastly; a large-cap report says nothing direct about either company’s orders.
Tue Nov 17Approximate sale date in the Fastly Form 144 notices. Form 144.Executed sales, if any, will appear in later Form 4 filings.
Wed Nov 18 · 13:00 ET / 19:00 Rome20-year Treasury bond auction. Treasury upcoming auctions.Long-end rate background for leveraged businesses such as Cleveland-Cliffs.
Thu Nov 19 · 08:30 ET / 14:30 RomeInitial jobless claims (U.S. Department of Labor).Labor-market background.
Fri Nov 20The Friday November 20 close is the fixed endpoint of this edition’s forward price comparison.Audit date only.

Previous-edition audit: keep the original dates and every case

The previous edition defined its forward interval as November 6 close to November 13 close. The table fills that exact interval for all five names, with the categories they carried in that edition. The final column shows the October 30–November 6 week that preceded it; it is context, not part of the audit.

Original tickerCategory in the previous editionNov 6 close · USDNov 13 close · USDFixed audit returnvs IWM · ppPrior Oct 30–Nov 6 return
SPSCBreakout failed · back below the averages81.9181.30-0.74%-2.16 pp-1.30%
CLFStated invalidation triggered · below $12.6211.4612.65+10.38%+8.97 pp-19.58%
EFORFailure deepened · below both averages34.3435.55+3.52%+2.11 pp-10.06%
FSLYFailed status retained · results delivered15.8516.62+4.86%+3.44 pp-31.44%
PENGDecline extended below $50.07 · reassessment41.8347.36+13.22%+11.81 pp-19.45%
IWMBenchmark273.67277.54+1.41%—-2.03%

The unweighted average of the five cases was +6.25%, compared with IWM +1.41% over the identical interval. Four of the five beat the benchmark; SPSC did not. The rebound followed a week in which the same five had averaged -16.37%, so it recovered only part of that loss. Over the last five audited weeks the record contains three shortfalls and two advantages against IWM. The failures are kept in the record with their original labels.

This is an accountability check of dated research, not a trading record or backtested strategy. There were no published executed holdings, allocations, execution prices or trading costs. Historical returns say nothing reliable about next week’s selection.

Other names checked: reasons and limits

These observations use the same November 13 cutoff. A name omitted from the developed five is not necessarily a poor company or a bearish forecast. Technical objections, incomplete business research and editorial capacity are different reasons; they are stated separately below.

Ticker or groupObserved reason for not developing a new case
INTR, STNEINTR +7.51% and STNE +5.46% for the week; closes remain 13.73% and 9.32% below SMA20, with falling intermediate averages. No company disclosure collected here explains the late-October gaps, so no case is built on them.
MIR, TENBMIR -1.28%, above SMA20 $17.12 and above SMA50 $16.31; TENB -3.25%, below SMA20 $44.59 and above SMA50 $39.75.
SPNT, MMS, QLYSSPNT +0.91%, above SMA20 $26.04 and above SMA50 $25.30; MMS -1.21%, above SMA20 $64.36 and above SMA50 $59.45; QLYS -9.17%, below SMA20 $202.93 and below SMA50 $190.98, after a $164.68 weekly low. No new business evidence collected here.
AVT, BB, SEZL, RXOAVT +5.92%, BB +1.83%, SEZL +3.46%, RXO +2.97%. Positions: AVT below SMA20 $87.62 and below SMA50 $93.80; BB above SMA20 $8.88 and above SMA50 $8.59; SEZL above SMA20 $138.67 and above SMA50 $125.55; RXO above SMA20 $28.24 and above SMA50 $25.11, in an unusually narrow range.
BKV, POWL, AMSC, EFXTBKV +9.69%, POWL +7.21%, AMSC +3.16%, EFXT +4.18%. All four rose but closed below SMA20; intermediate slopes: -4.87%, -4.59%, -2.63% and +0.07%.
AIR, PRGS, CNXCAIR -0.72%, above SMA20 $104.64 and above SMA50 $108.40; PRGS +0.64%, below SMA20 $44.47 and above SMA50 $41.77; CNXC +7.92%, above SMA20 $31.10 and above SMA50 $28.90.

How the numbers and charts were calculated

All displayed closes, daily chart candles and technical measures come from consolidated daily bars through November 13, 2026. The five charts display the latest 60 sessions; earlier observations supply the moving averages. SMA20 and SMA50 are arithmetic means of the latest 20 and 50 closes; the intermediate slope compares SMA50 with its value ten sessions earlier. Prices shown are completed-session closes, not live quotes or weekend/intraday prices.

Weekly price change = (November 13 close / November 6 close − 1) × 100. Relative strength is that stock return minus IWM’s return, in percentage points. Because the previous edition’s forward window was November 6 to November 13, the audit and the weekly change use the same interval this week. These are unweighted price-return comparisons, without reinvested dividends, transaction costs, slippage or a hypothetical executed position. A relative gain can coexist with an absolute loss.

Volume ratio = November 13 volume divided by the average of the preceding 20 sessions, excluding November 13. The separate liquidity figure is the average of the latest 20 sessions, including November 13. The prior-20-session high excludes November 13, while the ten-session low includes it. Distances above or below SMA20 describe extension, not fair value.

The November 6 closes recalculated from this week’s series match the closes published in the previous edition for all five cases and for IWM. Volume equivalence between different data providers is not claimed.

The indicative market capitalizations below apply third-party share-count estimates to November 13 closes. They are not a newly computed fully diluted valuation and can differ from a calculation using an SEC cover-page share count; repurchases, issuance, stock compensation and convertible financing can change the relevant share base. The $300 million–$10 billion band is this rubric’s editorial definition, not a universal index classification.

TickerIndicative market value · November 13Source and limitation
SPSC$2.881 billionThird-party share-count estimate; common equity, not enterprise value or fully diluted value.
CLF$7.218 billionThird-party share-count estimate; common equity, not enterprise value or fully diluted value.
EFOR$1.461 billionThird-party share-count estimate; common equity, not enterprise value or fully diluted value.
FSLY$2.679 billionThird-party share-count estimate; common equity, not enterprise value or fully diluted value.
PENG$2.853 billionThird-party share-count estimate; common equity, not enterprise value or fully diluted value.

A selective weekly research filter

The aim is to improve the quality and traceability of research. A headline, a conference appearance, an analyst mention or a large weekly percentage alone is insufficient. Cases may have different risk profiles; any exception to the preferred filter is identified, rather than being presented as a fully qualified technical setup.

First: security, size and liquidity

U.S.-listed non-healthcare equities, price above $5 and an indicative $300 million–$10 billion common-equity value. The original selection requested positive weekly performance, price above SMA20/SMA50 and average volume above 500,000 shares. The developed cases were recalculated at one completed-session cutoff. SPSC’s latest 20-session volume average is only just above 500,000 shares, so its retained research status still carries a liquidity caveat.

Second: evidence belonging to the issuer

Results, cash conversion, contract economics, financing and precise news dates. An IDIQ ceiling is not guaranteed revenue; a product launch is not quantified monetization; guidance is not a reported result. A tax benefit can lift net income without representing recurring operating profit. Each earnings and cash-flow figure refers to its own reporting period.

Third: demand for the shares

Relative strength, location against the averages, direction of the intermediate trend, participation and extension are assessed together. A positive percentage can coexist with weak volume or a stretched price. A breakout requires a close and subsequent acceptance. Five weeks of audits show both sides: FSLY and PENG reversed sharply, SPSC and EFOR broke out and failed, CLF, EFOR and PENG closed below references named in advance, and in the latest week four of the five rebounded ahead of IWM; every condition met or failed is reported, not removed.

Fourth: observable failure and a fixed audit

Each case has price references and business risks that could change its interpretation. References are historical chart observations, not entry or stop orders. Every original name stays in the future comparison, including disclosed exceptions. One week’s outcome is too little evidence to establish a repeatable advantage.

No complete options-implied move, analyst-consensus model or positioning study is included. This edition therefore makes no quantified valuation-advantage claim, short-squeeze claim or success-probability estimate. Readers should add their own current information and risk assessment before any financial decision.

What each company report examines

Catalysts and contracts

Government awards, commercial wins, product launches, regulatory decisions and strategic milestones that can change what the market expects, each with the document that establishes it.

Earnings and execution

Revenue quality, margins, backlog conversion, guidance and the distance between what management said it would deliver and what it delivered.

Capital structure

Cash, runway, debt, share issuance, warrants, convertibles and the at-the-market programmes that quietly reshape per-share value.

Risk and volatility

Liquidity, valuation, concentration, ownership, insider activity and the specific events that would invalidate the prevailing narrative.

Sources and boundaries

  • Company investor-relations announcements and SEC filings are linked beside the relevant cases. An issuer release and its SEC exhibit are two forms of the same management disclosure, not independent opinions.
  • Consolidated daily bars supply the dated prices, candles and calculations; a dated screening snapshot supplies the capitalization estimates. No live-price claim is made.
  • The Federal Reserve meeting calendar, the Census and BLS November release schedules and TreasuryDirect supply the macro dates. Company events calendars and announcements supply the verified later earnings dates.
  • Technical interpretations, confirmation conditions and risk scenarios are Merlintrader analysis. They are distinguished from reported facts and management forecasts; unverified rumours, customer economics and analyst targets are not added.

Prepared November 14, 2026, with completed-session market data through November 13. Company financial periods and announcement dates are preserved individually. Later disclosures can change the assessment. No automatic follow-up or ongoing monitoring is implied.

Related research: Weekly Market Pulse, Insider Trading Weekly and Free Biotech Catalyst Calendar.

Get the weekly list as it goes live

Join the Merlintrader Telegram channel for the weekly list, market recaps and research updates the moment they are published.

Join @merlintraderpub_com on Telegram

Educational research only. This page is published for educational and informational purposes. It is not investment advice, not a recommendation, and not an offer or solicitation to buy or sell any security. Merlintrader is not a registered investment adviser or broker-dealer. Small and mid-cap securities can be highly volatile and may have limited liquidity. Company filings, market data and scheduled dates can be revised by the issuer or the agency that published them, and past performance does not indicate future results. Always do your own research and consult a licensed financial adviser before making any investment decision. Full disclaimer: merlintrader.com/disclaimer.

Merlintrader — educational use only. Community: r/MerlintraderPub · Telegram @merlintraderpub_com

Latest Small-Cap and Mid-Cap Research